These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 17999987)

  • 1. Loss of type III transforming growth factor beta receptor expression increases motility and invasiveness associated with epithelial to mesenchymal transition during pancreatic cancer progression.
    Gordon KJ; Dong M; Chislock EM; Fields TA; Blobe GC
    Carcinogenesis; 2008 Feb; 29(2):252-62. PubMed ID: 17999987
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TbetaRIII suppresses non-small cell lung cancer invasiveness and tumorigenicity.
    Finger EC; Turley RS; Dong M; How T; Fields TA; Blobe GC
    Carcinogenesis; 2008 Mar; 29(3):528-35. PubMed ID: 18174241
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The type III transforming growth factor-beta receptor as a novel tumor suppressor gene in prostate cancer.
    Turley RS; Finger EC; Hempel N; How T; Fields TA; Blobe GC
    Cancer Res; 2007 Feb; 67(3):1090-8. PubMed ID: 17283142
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epithelial-mesenchymal transition in ovarian cancer progression: a crucial role for the endothelin axis.
    Bagnato A; Rosanò L
    Cells Tissues Organs; 2007; 185(1-3):85-94. PubMed ID: 17587812
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Loss of betaglycan expression in ovarian cancer: role in motility and invasion.
    Hempel N; How T; Dong M; Murphy SK; Fields TA; Blobe GC
    Cancer Res; 2007 Jun; 67(11):5231-8. PubMed ID: 17522389
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting endogenous transforming growth factor beta receptor signaling in SMAD4-deficient human pancreatic carcinoma cells inhibits their invasive phenotype1.
    Subramanian G; Schwarz RE; Higgins L; McEnroe G; Chakravarty S; Dugar S; Reiss M
    Cancer Res; 2004 Aug; 64(15):5200-11. PubMed ID: 15289325
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vascular endothelial growth factor receptor-1 activation mediates epithelial to mesenchymal transition in human pancreatic carcinoma cells.
    Yang AD; Camp ER; Fan F; Shen L; Gray MJ; Liu W; Somcio R; Bauer TW; Wu Y; Hicklin DJ; Ellis LM
    Cancer Res; 2006 Jan; 66(1):46-51. PubMed ID: 16397214
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epithin, a target of transforming growth factor-beta signaling, mediates epithelial-mesenchymal transition.
    Lee HS; Kim C; Kim SB; Kim MG; Park D
    Biochem Biophys Res Commun; 2010 May; 395(4):553-9. PubMed ID: 20398629
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sp1 is required for transforming growth factor-beta-induced mesenchymal transition and migration in pancreatic cancer cells.
    Jungert K; Buck A; von Wichert G; Adler G; König A; Buchholz M; Gress TM; Ellenrieder V
    Cancer Res; 2007 Feb; 67(4):1563-70. PubMed ID: 17308095
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inflammatory cytokines augments TGF-beta1-induced epithelial-mesenchymal transition in A549 cells by up-regulating TbetaR-I.
    Liu X
    Cell Motil Cytoskeleton; 2008 Dec; 65(12):935-44. PubMed ID: 18792103
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thyroid transcription factor-1 inhibits transforming growth factor-beta-mediated epithelial-to-mesenchymal transition in lung adenocarcinoma cells.
    Saito RA; Watabe T; Horiguchi K; Kohyama T; Saitoh M; Nagase T; Miyazono K
    Cancer Res; 2009 Apr; 69(7):2783-91. PubMed ID: 19293183
    [TBL] [Abstract][Full Text] [Related]  

  • 12. N-cadherin expression and epithelial-mesenchymal transition in pancreatic carcinoma.
    Nakajima S; Doi R; Toyoda E; Tsuji S; Wada M; Koizumi M; Tulachan SS; Ito D; Kami K; Mori T; Kawaguchi Y; Fujimoto K; Hosotani R; Imamura M
    Clin Cancer Res; 2004 Jun; 10(12 Pt 1):4125-33. PubMed ID: 15217949
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nuclear factor-kappaB-mediated transforming growth factor-beta-induced expression of vimentin is an independent predictor of biochemical recurrence after radical prostatectomy.
    Zhang Q; Helfand BT; Jang TL; Zhu LJ; Chen L; Yang XJ; Kozlowski J; Smith N; Kundu SD; Yang G; Raji AA; Javonovic B; Pins M; Lindholm P; Guo Y; Catalona WJ; Lee C
    Clin Cancer Res; 2009 May; 15(10):3557-67. PubMed ID: 19447876
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TGFbeta Type III and TGFbeta Type II receptors have distinct activities during epithelial-mesenchymal cell transformation in the embryonic heart.
    Boyer AS; Runyan RB
    Dev Dyn; 2001 Aug; 221(4):454-9. PubMed ID: 11500982
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiple transforming growth factor-beta isoforms and receptors function during epithelial-mesenchymal cell transformation in the embryonic heart.
    Mercado-Pimentel ME; Runyan RB
    Cells Tissues Organs; 2007; 185(1-3):146-56. PubMed ID: 17587820
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AZGP1 is a tumor suppressor in pancreatic cancer inducing mesenchymal-to-epithelial transdifferentiation by inhibiting TGF-β-mediated ERK signaling.
    Kong B; Michalski CW; Hong X; Valkovskaya N; Rieder S; Abiatari I; Streit S; Erkan M; Esposito I; Friess H; Kleeff J
    Oncogene; 2010 Sep; 29(37):5146-58. PubMed ID: 20581862
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TGF-beta1 causes epithelial-mesenchymal transition in HaCaT derivatives, but induces expression of COX-2 and migration only in benign, not in malignant keratinocytes.
    Räsänen K; Vaheri A
    J Dermatol Sci; 2010 May; 58(2):97-104. PubMed ID: 20399617
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dissecting the role of TGF-beta type I receptor/ALK5 in pancreatic ductal adenocarcinoma: Smad activation is crucial for both the tumor suppressive and prometastatic function.
    Schniewind B; Groth S; Sebens Müerköster S; Sipos B; Schäfer H; Kalthoff H; Fändrich F; Ungefroren H
    Oncogene; 2007 Jul; 26(33):4850-62. PubMed ID: 17297450
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Soluble type II transforming growth factor-beta (TGF-beta) receptor inhibits TGF-beta signaling in COLO-357 pancreatic cancer cells in vitro and attenuates tumor formation.
    Rowland-Goldsmith MA; Maruyama H; Kusama T; Ralli S; Korc M
    Clin Cancer Res; 2001 Sep; 7(9):2931-40. PubMed ID: 11555612
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TGF beta (transforming growth factor beta) receptor type III directs clathrin-mediated endocytosis of TGF beta receptor types I and II.
    McLean S; Di Guglielmo GM
    Biochem J; 2010 Jul; 429(1):137-45. PubMed ID: 20406198
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.